2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2017-3-3-74-811194Archive categoriesQUANTITATIVE DETERMINATION OF THE INNOVATIVE NEOPIOID ANALGETIC IN A MUKOADAGESIVE DOSAGE FORMQUANTITATIVE DETERMINATION OF THE INNOVATIVE NEOPIOID ANALGETIC IN A MUKOADAGESIVE DOSAGE FORMAvtinaTatiana V.AvtinaTatiana V.avtina_t@bsu.edu.ruPokrovskiiMikhail V.PokrovskiiMikhail V.pokrovskii@bsuedu.ruKulikovAleksandr L.KulikovAleksandr L.kulikov@bsu.edu.ruAvtinaNatalia V.AvtinaNatalia V.20173300

Introduction. The TRPA1 channel blocker (ZC02-0012) is an innovative drug belonging to the class of non-opioid analgesics. According to the results of his pharmacokinetic studies, a decision was made on the expediency of developing its prolonged dosage form, which was chosen as biopolymer films, which are one of the innovative long-acting dosage forms intended for topical application and possessing a number of positive properties. In order to standardize the dosage form in terms of the "Quantitative Content" indicator, there was developed a method using a highly efficient liquid chromatograph with a diode-array detector. Materials and methods. The subject of the study includes biopolymer films containing a non-opioid analgesic, a blocker of TRPA1 channels (ZC02-0012). The quantitative content of the non-opioid analgesic was confirmed by HPLC under the following conditions: instrument – a liquid chromatograph with a working pressure range of 0-60 mPa; detector is spectrophotometric with a diode array system operating in the range of 195-400 nm; protective column – Zorbax SB C8 12.5 × 4.6 mm with a particle size of 5.0 μm; column – Zorbax SB C8 150 × 4.6 mm with a particle size of 3.5 μm; mobile phase A – 10.35 g/l KCLO4 + 2.6 ml/l HCLO4; mobile phase B – acetonitrile; the temperature of the sample thermostat is 5ºC; the temperature of the column thermostat is 40ºC; injection volume – 20 μl; retention time of ZC02-0012 is about 7.0 minutes; wavelength is 291 nm (190-400 nm for identification); separation mode – linear gradient elution. The method of quantitative determination of a non-opioid analgesic in a biopolymer film was studied by validation characteristics: specificity, accuracy, linearity and precision. Results and discussion. Validation procedure proved the accuracy, linearity and precision of the method of quantitative determination of a non-opioid analgesic in a biodegradable polymeric film in the concentration range of 80-120% of the nominal content of a pharmacologically active substance. The validation characteristics of the method were obtained: accuracy (er max – 0.31%, er average – 0.07%, Δer = 0.04%); linearity (linear dependence of optical density on analgesic concentration is observed, r = 0.99987); precision (Sraverage – 1.45%, εaverage – 1.03%). The quantitative content of the non-opioid analgesic in the biopolymer film ranges from 90% to 110%. Conclusion. The developed and validated method for the quantitative determination of the non-opioid analgesic was successfully applied to standardize the biopolymer film ZC02-0012 in terms of the "Quantitative content" indicator.

Introduction. The TRPA1 channel blocker (ZC02-0012) is an innovative drug belonging to the class of non-opioid analgesics. According to the results of his pharmacokinetic studies, a decision was made on the expediency of developing its prolonged dosage form, which was chosen as biopolymer films, which are one of the innovative long-acting dosage forms intended for topical application and possessing a number of positive properties. In order to standardize the dosage form in terms of the "Quantitative Content" indicator, there was developed a method using a highly efficient liquid chromatograph with a diode-array detector. Materials and methods. The subject of the study includes biopolymer films containing a non-opioid analgesic, a blocker of TRPA1 channels (ZC02-0012). The quantitative content of the non-opioid analgesic was confirmed by HPLC under the following conditions: instrument – a liquid chromatograph with a working pressure range of 0-60 mPa; detector is spectrophotometric with a diode array system operating in the range of 195-400 nm; protective column – Zorbax SB C8 12.5 × 4.6 mm with a particle size of 5.0 μm; column – Zorbax SB C8 150 × 4.6 mm with a particle size of 3.5 μm; mobile phase A – 10.35 g/l KCLO4 + 2.6 ml/l HCLO4; mobile phase B – acetonitrile; the temperature of the sample thermostat is 5ºC; the temperature of the column thermostat is 40ºC; injection volume – 20 μl; retention time of ZC02-0012 is about 7.0 minutes; wavelength is 291 nm (190-400 nm for identification); separation mode – linear gradient elution. The method of quantitative determination of a non-opioid analgesic in a biopolymer film was studied by validation characteristics: specificity, accuracy, linearity and precision. Results and discussion. Validation procedure proved the accuracy, linearity and precision of the method of quantitative determination of a non-opioid analgesic in a biodegradable polymeric film in the concentration range of 80-120% of the nominal content of a pharmacologically active substance. The validation characteristics of the method were obtained: accuracy (er max – 0.31%, er average – 0.07%, Δer = 0.04%); linearity (linear dependence of optical density on analgesic concentration is observed, r = 0.99987); precision (Sraverage – 1.45%, εaverage – 1.03%). The quantitative content of the non-opioid analgesic in the biopolymer film ranges from 90% to 110%. Conclusion. The developed and validated method for the quantitative determination of the non-opioid analgesic was successfully applied to standardize the biopolymer film ZC02-0012 in terms of the "Quantitative content" indicator.

polymer filmquantitative determinationnon-opioid analgesicblocker TRPA1 channelshigh-performance liquid chromatographypolymer filmquantitative determinationnon-opioid analgesicblocker TRPA1 channelshigh-performance liquid chromatographyСписок литературыLazarev A.I., Chestnikova S.E., Erofeeva L.N., Pankrusheva T.A. Use of polymeric application antibacterial films for the treatment of patients with perforated odontogenic maxillary sinusitis. Russian otorhinolaryngology. 2007. 2. Рр. 3-6. Russian.Pankrusheva T.A., Avtina N.V., Pankrushev A.A. The Medicamental Forms Used in Local Therapy of Inflammatory Diseases of Parodontium. Journal of New Medical Technologies. 2009. 16 (1). Pp. 139-141. Russian.Рankrusheva T.A., Erofeeva L.N., Maravina I.N., Chekmareva M.S., Avtina T.V., Avtina N.V. Polymeric medicinal films for the treatment of diseases of the mucous membranes. Uchenye zapiski Orlovskogo gosudarstvennogo universiteta. Seriya: Estestvennye, tekhnicheskie i medicinskie nauki. 2014. 1 (7). Pp. 211-212. Russian.Pankrusheva T.A., Avtina N.V., Pankrushev A.A., Nesterova A.V., Medvedeva O.A. Formulation of medicinal drugs for the treating inflammatory parodontium diseases. Proceedings of Voronezh State University. Series: Chemistry. Biology. Pharmacy. 2003. 2. Pp. 214-219. Russian.Nie Y., Huang C., Zhong S., Wortley M.A., Luo Y., Luo W., Xie Y., Lai K., Zhong N. Nie Y. Cigarette smoke extract (CSE) induces transient receptor potential ankyrin 1(TRPA1) expression via activation of HIF1αin A549 cells. Free Radic Biol Med. 2016. 99. Рр. 498-507.Matta J.A., Cornett P.M., Miyares R.L., Abe K., Sahibzada N., Ahern G.P. General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci USA. 2008. 105 (25). Pp. 8784–89.Beskhmelnitsyna E.A., Korokin M.V., Avtina T.V., Martynova O.V., Varavin I.I., Tishin A.N. Ion channel TRPA1 is a promising therapeutic target for treatment of pain. Research result: pharmacology and clinical pharmacology. 2015.1 (1 (1)). Pp. 20-22. doi: 10.18413/2500-235X-2015-1-4-21-24.Jordt S.E., Bautista D.M., Chuang H.H. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature. 2004. 427 (6971). Рp. 260–265.Danilenko L.M., Klochkova G.N., Kizilova I.V., Korokin M.V. Metabolic cardioprotection: new concepts in implementation of cardioprotective effects of meldonium. Research result: pharmacology and clinical pharmacology. 2016. 2 (3). Рp. 95-100. doi: 10.18413/2500-235X -2016-2-3-95-100.Adi-Dako O., Bekoe Oppong S., Ofori-Kwakye K., Appiah E., Peprah P. Novel HPLC Analysis of Hydrocortisone in Conventional and Controlled-Release Pharmaceutical Preparations. J Pharm (Cairo). 2017. 2017: 9495732. doi: 10.1155/2017/9495732.Maher H.M., Al-Taweel S.M., Alshehri M.M., Alzoman N.Z. Novel stereoselective high-performance liquid chromatographic method for simultaneous determination of guaifenesin and ketorolac enantiomers in human plasma. Chirality. 2014. 26 (10). Pp. 629-39. doi: 10.1002/chir.22354.Ragulina V.A., Kostina D.A., Dovgan A.P., Burda Y.E., Nadezhdin S.V. Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology. Research result: pharmacology and clinical pharmacology. 2017.3 (1). Рp. 114-124. doi: 10.18413/2500-235X-2017-3-1-114-124.Ivanovic D., Medenica M., Malenovic A., Jancic B., Misljenovic Dj. Optimization of theRP-HPLC method for multicomponent analgetic drug determination. Boll Chim Farm. 2003. 142 (9).Pp. 386-389.Bogus S.K., Dukhanin A.S., Kucheryavenko A.F., Vinakov D.V., Suzdalev K.F., Galenko-Yaroshevsky P.A. Pleyotropic antiaggregant effects of an innovative antiarrhythmic of class III SS-68, an indole derivative. Research result: pharmacology and clinical pharmacology. 2017. 3 (2). Pp. 3-13. doi: 10.18413/2313-8971-2017-3-2-3-13.Al-Zoman N.Z., Maher H. M., Al-Subaie A. Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. Chem Cent J. 2017. 11. Pp. 1-8. doi: 10.1186/s13065-016-0232-6.Skerratt S. Chapter Three – Recent Progress in the Discovery and Development of TRPA1 Modulators. Prog Med Chem. 2017. 56. Pp. 81-115.Mukhopadhyay I., Kulkarni A., Aranake S., Karnik P., Shetty M., Thorat S., Ghosh I. Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic. PLoS One. 2014. 9 (5). P. e97005.Trevisani M., Siemens J., Materazzi S. 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci USA. 2007. 104 (33). Pp. 13519–24.Nakao S., Nakao S., Mabuchi M., Wang S., Kogure Y., Shimizu T., Noguchi K., Tanaka A., Dai Y. Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor. Bioorg Med Chem Lett. 2017.27 (14). Pр. 3167-3172.Belal T.S., El-Kafrawy D.S., Mahrous M.S., Abdel-Khalek M.M., Abo-Gharam A.H. Validatedspectrophotometric and chromatographic methods for simultaneous determination of ketorolac tromethamine and phenylephrine hydrochloride. Ann Pharm Fr. 2016. 74 (4). Pp. 267-82. doi: 10.1016/j.pharma.2015.12.006.